Rangi K Kandane-Rathnayake

List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/189865/rangi-k-kandane-rathnayake-publications-by-citations.pdf$

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23 420 12 20 g-index

26 616 4.9 avg, IF L-index

#	Paper	IF	Citations
23	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 62	5.7	59
22	Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Scientific Reports, 2016 , 6, 3460	044.9	53
21	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000157	4.6	53
20	Discordance of patient and physician health status concerns in systemic lupus erythematosus. <i>Lupus</i> , 2018 , 27, 501-506	2.6	35
19	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , 2016 , 18, 260	5.7	29
18	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology, The</i> , 2019 , 1, e95-e102	14.2	26
17	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. <i>Scientific Reports</i> , 2016 , 6, 29909	4.9	22
16	The Dose-Response Association between Nitrogen Dioxide Exposure and Serum Interleukin-6 Concentrations. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	22
15	The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. <i>Blood Transfusion</i> , 2015 , 13, 86-99	3.6	22
14	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e24-e30	14.2	22
13	Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 8	5.7	16
12	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 425-433	2.3	14
11	Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , 2018 , 8, 3268	4.9	12
10	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1289-1295	4.7	12
9	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1255-1257	2.3	9
8	Outcomes of patients admitted to hospital medical units with back pain. <i>Internal Medicine Journal</i> , 2019 , 49, 316-322	1.6	5
7	Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. <i>Lupus</i> , 2019 , 28, 1669-1677	2.6	4

LIST OF PUBLICATIONS

6	Use of recombinant activated factor VII in Jehovah Witness patients with critical bleeding. ANZ Journal of Surgery, 2013, 83, 155-60	1	1
5	Associations between physicians Wglobal assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study. <i>Lupus</i> , 2021 , 30, 1586-15	5 2 5 ⁶	1
4	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021 , 60, 5185-5193	3.9	1
3	Clinician-reported outcome measures in lupus trials: a problem worth solving. <i>Lancet Rheumatology, The</i> , 2021 , 3, e595-e603	14.2	1
2	Whot at target Worevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study <i>Arthritis Research and Therapy</i> , 2022 , 24, 70	5.7	1
1	POS0028 DEFINING THE PREVALENCE OF UNMET NEED IN SLE: DATA FROM A LARGE MULTINATIONAL LONGITUDINAL SLE COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 218-219	2.4	